Key enabling technologies for optical communications at 2000 nm

This paper discusses the potential for opening a new wavelength window at the 2 μm waveband for optical communications, showing current limitations of the system’s performance. It focuses on novel results for key enabling technologies, including the analysis of laser injection locking at this waveband, an improved responsivity for bulk and strained InGaAs edge-couple detectors, and also an increased gain profile for thulium-doped fiber amplifiers

Development of thulium-doped fibre amplifiers for the 2μm waveband

In this paper we show the analysis of Thulium Doped Fibre Amplifier(TDFA) gain dependence on pump laser wavelength and thulium doped fibre length. Thulium doped fibres of lengths varying from 0.5m to 3m are pumped with 785nm and 1550nm lasers in single and dual pumping schemes. Small signal gain up to 16dB was achieved at 2μm for a low pump power of 150mW. A potential wide amplifications bandwidth ranging from 1680nm to 2025nm is observed in the Amplified Spontaneous Emission(ASE) spectrum

Managing professional jurisdiction and domestic energy use

Professionals involved in organizing and undertaking domestic works, such as extensions, maintenance and refurbishment, have an important role in influencing how homes are configured and how occupants live within them. Despite this, the professional identities of these actors, and their impact on domestic energy use, is often overlooked. In response, this paper argues that one useful way of examining their influence is to consider how professional identities shape everyday working practices in relation to clients. Data from two UK interview and observation studies are combined: one with heating installers and the other with architects. The data are analysed using concepts from Abbott’s ‘system of professions’ framework that focuses on how the routine working practices of professional groups are born of how they see themselves and the tasks for which they are responsible. This comparison provides insights into how these two groups manage their professional ‘jurisdictions’ during their client interactions and what this means for policy-makers and industry representatives hoping to influence their work in pursuit of less carbon-intensive living. It also points to the value of further in-depth studies that explore how the routine management of professional jurisdiction impacts upon domestic energy use in a range of contexts

epiCaPture: a urine DNA methylation test for early detection of aggressive prostate cancer

Purpose Liquid biopsies that noninvasively detect molecular correlates of aggressive prostate cancer (PCa) could be used to triage patients, reducing the burdens of unnecessary invasive prostate biopsy and enabling early detection of high-risk disease. DNA hypermethylation is among the earliest and most frequent aberrations in PCa. We investigated the accuracy of a six-gene DNA methylation panel (Epigenetic Cancer of the Prostate Test in Urine [epiCaPture]) at detecting PCa, high-grade (Gleason score greater than or equal to 8) and high-risk (D'Amico and Cancer of the Prostate Risk Assessment] PCa from urine. Patients and Methods Prognostic utility of epiCaPture genes was first validated in two independent prostate tissue cohorts. epiCaPture was assessed in a multicenter prospective study of 463 men undergoing prostate biopsy. epiCaPture was performed by quantitative methylation-specific polymerase chain reaction in DNA isolated from prebiopsy urine sediments and evaluated by receiver operating characteristic and decision curves (clinical benefit). The epiCaPture score was developed and validated on a two thirds training set to one third test set. Results Higher methylation of epiCaPture genes was significantly associated with increasing aggressiveness in PCa tissues. In urine, area under the receiver operating characteristic curve was 0.64, 0.86, and 0.83 for detecting PCa, high-grade PCa, and highrisk PCa, respectively. Decision curves revealed a net benefit across relevant threshold probabilities. Independent analysis of two epiCaPture genes in the same clinical cohort provided analytical validation. Parallel epiCaPture analysis in urine and matched biopsy cores showed added value of a liquid biopsy. Conclusion epiCaPture is a urine DNA methylation test for high-risk PCa. Its tumor specificity out-performs that of prostate-specific antigen (greater than 3 ng/mL). Used as an adjunct to prostate-specific antigen, epiCaPture could aid patient stratification to determine need for biopsy

Prognostic value of the 6-gene OncoMasTR test in hormone receptor–positive HER2-negative early-stage breast cancer: Comparative analysis with standard clinicopathological factors

Aim: The aim of the study was to assess the prognostic performance of a 6-gene molecular score (OncoMasTR Molecular Score [OMm]) and a composite risk score (OncoMasTR Risk Score [OM]) and to conduct a within-patient comparison against four routinely used molecular and clinicopathological risk assessment tools: Oncotype DX Recurrence Score, Ki67, Nottingham Prognostic Index and Clinical Risk Category, based on the modified Adjuvant! Online definition and three risk factors: patient age, tumour size and grade. Methods: Biospecimens and clinicopathological information for 404 Irish women also previously enrolled in the Trial Assigning Individualized Options for Treatment [Rx] were provided by 11 participating hospitals, as the primary objective of an independent translational study. Gene expression measured via RT-qPCR was used to calculate OMm and OM. The prognostic value for distant recurrence-free survival (DRFS) and invasive disease-free survival (IDFS) was assessed using Cox proportional hazards models and Kaplan-Meier analysis. All statistical tests were two-sided ones. Results: OMm and OM (both with likelihood ratio statistic [LRS] P Discussion: Both OncoMasTR scores were significantly prognostic for DRFS and IDFS and provided additional prognostic information to the molecular and clinicopathological risk factors/tools assessed. OM was also the most accurate risk classification tool for identifying DR. A concise 6-gene signature with superior risk stratification was shown to increase prognosis reliability, which may help clinicians optimise treatment decisions. Trial registration: ClinicalTrials.gov NCT02050750 NCT00310180.</p